Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right with You!!!
Patience all that's needed! Shares getting soaked up.
I would imagine anything is possible considering the maturing advancement in NIH pre-clinicals for a high profile national pharma need to mitigate the opioid crisis.
Exactly the point.
Savvy investors accumualting
Traders are typical ignorant to the DD, rather watching the ticks and hoping they can scalp tickets to the rocket ride vs. purchasing them at early bird prices.
Setting it and forgetting it. Potential is great, and so is price IMO
$RSPI
Jeff not liking what you are saying. We need these postes and posters. -J
While I appreciate the news. Continued publishing of the info on big stages and contact with BP will drive this company into the clouds!
Update on the website: RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury March 26, 2024
https://respirerx.com/wp-content/uploads/2024/03/RespireRx-SCI-Bladder-paper-final-approved-for-distribution.pdf
Rspi message board has a ton of ignorant posters.
You can tell by the language used..
Definitely not savvy...
Specifically terms, goes to show that, if you posters cannot even get terms correct, I question all the supposedly DD.
Terms are important..
Scary that those are the people buying this stock.
Wow, hahaha
Agree with that. If some debt holders want to convert at giveaway prices, there is going to be plenty of saavy folks happy to absorb them. Been happening for months here.
The one month chart shows RSPI coming up off a double bottom bounce
lol..ulness we get a complete clusterfuk of selling it aint happening.
Hit the ask.
I got a few more milly to go to catch up with you!!
Want to get there before the run starts.
Yes it would be nice , I would gather up atleast 5m GLTA
That's my target number. Anything more is golden.
I'll take trips. I'd love it for a couple of days of downward trend into about 0005. That would be fine.
Just slapped the ask for a million , just goal my goal of 10M so now a wait game . GLTA
Very little interest here it seems for so much potential! Peeps selling into .001 today … trips again?
Hmmm. I supposed we can speculate. Pharmas like this are investments and you accumulate and tuck shares away, IMO.
However, a few thoughts on your question. They pushed some debt payments back to early 2025. Looking for funding for phase 2 trials on SCI/ADHD later in year. Seems like they are expecting an influx of cash between now and then.
I guess a few other thoughts, they bring in a VP/dealmaker 4 months ago and the volume has been much higher absorbing conversions and dilution. If they are making progress in tier 3 NIH clinicals, it feels like we should hear something along those lines sooner than later, although sooner can be months away too. The CEO mentioned in the short-term however hoping to see purse strings open to support the pain/epilepsy drug development. All sounds to me like they are looking for a partner or partners to go down this path. So would a big pharma need full validity in tier 3 NIH to move in or is all the other preclinicals and inferences enough confidence? Also seems to me that if tier 3 NIH legitamizes EPM-11-81 as a strong candidate and grant money becomes available that the valuation of the IP goes up enormously at that point.
Risk v. Reward
Someone was asking about some expertise into understanding the science behind RespireRx’s pipeline. In particular, what are the concrete constraints, and challenges involved with developing safe drugs that act on the AMPA receptor. I commented a bit on this before, Ampakines push a very powerful button in the brain, and issues of toxicity have to be resolved effectively through a solid understanding of pharmacology.
Here’s a new study released as preprint on BioRXiv, you can’t get more up-to-date than that. Basically, how toxicity can arise in looked at in detail, and how to prevent it is getting better understood.
https://www.biorxiv.org/content/10.1101/2024.01.28.577446v1.abstract
“The same linkage was not observed using high concentrations of the low impact AMPAkines, CX516 (Ampalex) and CX717. We also demonstrate that CX614 produces neuronal hyper-excitability at therapeutic doses while the newer generation low impact AMPAkine CX1739 is safe at exceedingly high doses.”
The biggest thing here is the time line for news. Is it in progress or are we looking at a year or more for big news?
Am wondering if instead of a buyout, a BP is offering funding with first option to buy on an individual drug level?
How otherwise could you value...set a sales price on what seems at this point to be 4 drugs with huge usefulness?
Has anything like this ever happened in the history of bp?
That is the conclusion I am coming too. Pharma is huge risk reward and only a small % of candidate drugs ever make it to the finish line. Yet, one passing through all of NIH preclinicals has better than average odds, IMO. Therefore, worth much more to the big pharma.
Non Addictive pain management is worth Billion's. We could be sitting on a gold mine here.
I feel the same.
Continuing to DD and trying to understand what the candidate drug for epilepsy and pain could be worth at preclinical stage and successfully completed with presumably robust pre-clinical studies via NIH program? Considering it could be multi-silver coins.
I stand corrected
The fact that the one debt holder restructured his notes for a year out tells me that he knows something big is coming! Again very glad to have built a nice position here, because on the right announcement we will be hitting multi pennies.
"Clearly one of the big pharmas woukd have the existing infrastructurestructure to bring the multiple drugs' efficacy to market sooner than later = win/win for all concerned"
Exactly. Thinking out loud. They have the OSA pipeline transferred to Australia for development and listing. Which no recent update and no reflection of the value in the market cap. They recently stated they want to do more clinicals on the SCI/ADHD drug, but maybe later, pending financing....
This leaves the KRM-II-81 for pain and epilepsy. They continually seem enthusiastic and optimistic about this drug and it has advanced to presumably final preclinical stages in the NIH program. Considering the unmet pharma needs and public awareness of opioid crisis, it is going to take a large pharma with all encompassing infrastructure/resources to push this. On the surface, it would seem this preclinical drug would have tremendous value now, but even moreso if the NIH program green lights it into human clinicals!
Yes. Excerpt from their PR below, my impression is the new guy was brought in as a closer or deal maker....
"Mr. Clodfelter has extensive experience providing business development, strategy, and valuation
consulting services to pharmaceutical, biotech and medical device companies, where he has led or
been a core member on over 30 international and domestic pharmaceutical licensing and device
negotiations ranging from preclinical to launched products. This experience extends across large
pharmaceutical, biotechnology and medical device companies. He previously held positions at Eli
Lilly and Co. in Corporate Strategy and Business Development. He was at Amylin Pharmaceuticals
in New Product Planning and Decision Sciences and was involved in multiple business
development activities. Following Amylin, Mr. Clodfelter was the Chief Executive Officer of
Medicus Biosciences and Abvance Therapeutics, both biotechnology firms based in California"
The finance guy who is part time and used to work for a BP, plus the board member Dr. Darius.
Will have to look back at someone's previous post for details on the finance guy who is new.
Who is the new talent
Am guessing that the connection between one certain BP and newer talent brought on board might indicate that certain BP having reached out to say willing to meet anyone's top dollar offer for whatever relationship they seek.
Clearly one of the big pharmas woukd have the existing infrastructurestructure to bring the multiple drugs' efficacy to market sooner than later = win/win for all concerned.
One Material Event👍️
Complete and total Patience here!
One day, even 1 hour can make the difference. I have witnessed it many times! Sometimes on the wrong side of the trade and missing out. Ugh. Not here. Good to be on board!
RSPI getting closer and closer to setting sail
Agreed. Reviewing all the filings one can find that insiders and institutional are lining up with equity positions and also a "payment event" position while pushing any debt payments back until early 2025. I am sure they know what their IP is worth and it is NOT the peanuts that is the current market cap here.
Word is starting to spread and people don't want to be without shares. One major press release of a partnership and we will be looking at multi-pennies. I am glad I built my position here!
OTCN was the only MM on the ask and now .0012s up and hit..THIN!!!
Anyone subscribing to this site, RespireRx is mentioned, but it’s behind a rather steep paywall:
https://www.bioworld.com/articles/706771-other-news-to-note-for-march-21-2024
Additional early-stage research and drug discovery news in brief, from: Respirerx Pharmaceuticals.
Hard to forecast timing on anything in the pharma world. I think and many here would probably agree, you either invest for the long haul or you dont bother. If you cant stand money tied up or want to constantly flip stocks, then that strategy will dissappoint here, IMO. Just like late last year when the stock out of the blue ran 200-300% that can happen any day here and you blink a few days later and next thing you know it is 1000-2000% higher. Although there is dilution, shares are tight as I believe those shares available in numbers are being soaked up by investors....
If you piece together the inferences and wordings of recent updates about their three primary drug platforms... The OSA drug they are awaiting manufacture of the new formulations per presentation. With roughly half of that funding looking to be in place and intent to list on the ASX, I can imagine they are only a few steps away from clinicals with the new formulations. I think we would all be interested in a status update on OSA. The recent PR on the spinal and ADHD candidate suggests trials later this year pending funding. That leaves the epilepsy/pain candidate drug in tier 3 of NIH. The CEO mentioned short term looking for opening up purse strings to support. Given the national attention to opioids, any promising drug that can mitigate the problem would be absolutely huge news and very valuable. I would speculate they are looking for a partner to help carry the ball across the goal line with respect to this drug candidate. As one can imagine, big pharma would highly seek this candidate for a multitude of reasons.
We as investors can send out the message to other Bio boards in an attempt to find Bio backgrounds that can shed some perspective on this. I've been in ENZ? and it appears that these individuals are taking forever to get some of these things done while this company moves 10 times as fast. They also communicate better than that other Bio company. This company appears to have a drive to achieve their vision as well as keep their shareholders up to date on that progress.
"Nothing gets sold without a salesperson."
You are spot on!
Drug reps prescribe for patients in the U.S.
Been that way for a few if not several decades.
They supposedly educate the doctors who then, supposedly up to speed, prescribe what the drug rep recommended.
With Rspi, the clinical data is out of the bag, but it takes, as you said, a bio background person to be able to explain it to enough of the decision makers enough of the time.
Simplification of such complexities, is a daunting challenge to say the least?
Rspi should be able to attract such talent given the monumental multiple positives they are working on?
We need someone with a Bio background that understands the application and testing process to take over the DD on this company. That info is the ticket to getting out ahead of all the other investors. I think this company is close to breaking out due to their results and where they are with so many potential drug candidates. The company appears to have their shit together in the way they continue to push ahead and continue to get positive results in much needed markets focusing on severe illnesses.
Looks like we have a winner today to the ignore club.
What a pos..
This has got to be a first..
RSPI continues to release positive PRs..
BUT...
This pos continues to sell off...
Where are all the positive posts??
If if if
When when when
Buy buy buy
Reality is, if the company PRs can't lift this pos into positive territory....
Then what makes you all think your posts have any effect on this pos???
But I'm the mean one, right!!.
I'm just soooo mean!!!
RSPI get it together..
You have shareholders that are expecting big things.
RSPI, Look at all the great posts..
Can you please prove me wrong??
Now the word needs to spread about this company to get it off the ground floor.
😄...can you say "April 15th"?
Followers
|
278
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
45355
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody fly_fisherman jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |